MPR Weekly Dose Podcast #272 — Idvynso Approved for HIV; Expanded Indication for Dupixent; Novel Tx Shows Promise for Pancreatic CA; Oral Semaglutide for Adolescents; GLP-1 Potential Knee OA Tx
Two-drug, single-tablet approved to replace current antiretroviral regimen; Dupixent approved for pediatric CSU; novel treatment significantly improves survival in metastatic pancreatic cancer; oral s...
24 Apr 11min
MPR Weekly Dose Podcast #271 — Foundayo Now Available, Meets Safety Endpoints; Filspari, Sdamlo Approved; FDA Encourages TRT Makers to Purse Label Expansion
Foundayo, an oral GLP-1, now available for weight loss; results from the ACHIEVE-4 trial; Filspari gains approval for FSGS; a new formulation of amlodipine, and the FDA signals support for broader use...
17 Apr 14min
MPR Weekly Dose Podcast #270 — High Dose Wegovy; Durvalumab Combo for Unresectable HCC; Generic Dapagliflozin; Yuviwel Now Available for Achondroplasia
High-dose Wegovy now available for additional weight reduction when clinically indicated; trial results for durvalumab combo treatment in patients with unresectable hepatocellular; generic dapaglifloz...
10 Apr 10min
MPR Weekly Dose Podcast #269 — Lifyorli, Avlayah Approved; Lyme Disease Vaccine Trial Results; Once-Weekly Basal Insulin Approved for T2DM
Lifyorli combo approved for ovarian cancer; mixed results from Lyme disease vaccine trial; treatment approved for rare Hunter syndrome and Awiqli gets approval as once-weekly basal insulin for type 2 ...
27 Mars 10min
MPR Weekly Dose Podcast #268 — Childhood Immunization Schedule Changes Blocked; High Dose Wegovy Gets Green Light; Hidradenitis Suppurativa Tx Indication Expanded; Triple Therapy Show Significant Weight Loss
A federal court blocks changes to the childhood immunization schedule by the recently appointed vaccine advisory committee; higher dose Wegovy injection gets green light; Cosentyx expanded to include ...
20 Mars 11min
MPR Weekly Dose Podcast #267 — Sotyktu, Leucovorin Gain Approval; Follicular Lymphoma Treatment Withdrawn; FDA to Review Potential Hypertension Drug
Sotyktu's approval expanded to encompass active psoriatic arthritis; the FDA approves leucovorin for rare disorder, not autism; safety concerns prompt Tazverik withdrawal; FDA to review potential new ...
12 Mars 12min
MPR Weekly Dose Podcast #266 — Generic Flovent HFA; Achondroplasia Tx Gains Approval; Dupixent Approved for Allergic Fungal Rhinosinusitis; Swallowable Gastric Balloon
Glenmark to launch the first generic version of Flovent HFA, expanding affordable access; achondroplasia treatment granted accelerated approval; Dupixent approved for allergic fungal rhinosinusitis; a...
6 Mars 11min
MPR Weekly Dose Podcast #265 — Wakix Approval Expanded; Psoriasis, Weight-Loss Combo Tx; Psilocybin Shows Promise in TRD; Remibrutinib for Chronic Inducible Urticaria; Injectable Regimen Benefits HIV Treatment Adherence
We explore the FDA's expansion of Wakix as the first non-scheduled treatment for pediatric cataplexy; a Taltz and Zepbound combo shows promise in skin clearance for patients with psoriasis and obesity...
20 Feb 12min
